Pirfenidone

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Covid19

Conditions

Covid19, ARDS

Trial Timeline

Nov 8, 2020 → Dec 31, 2022

NCT ID

NCT04653831

About Pirfenidone

Pirfenidone is a pre-clinical stage product being developed by Roche for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04653831. Target conditions include Covid19, ARDS.

What happened to similar drugs?

4 of 16 similar drugs in Covid19 were approved

Approved (4) Terminated (5) Active (9)

❌AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3

✅Icosapent ethylAmarin CorporationApproved

❌BaricitinibEli LillyPhase 3

🔄LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3

✅bamlanivimabEli LillyApproved

🔄Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3

🔄Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04653831	Pre-clinical	Completed	Nov 8, 2020	Dec 31, 2022	Covid19
NCT03385668	Phase 2	Completed	Jan 31, 2018	Jul 24, 2020	Pulmonary Fibrosis
NCT03208933	Phase 3	Completed	Oct 23, 2017	Nov 13, 2019	Idiopathic Pulmonary Fibrosis
NCT03115619	Pre-clinical	Completed	Apr 18, 2017	Jan 10, 2020	Idiopathic Pulmonary Fibrosis
NCT02525484	Phase 1	Completed	Aug 1, 2015	Aug 1, 2015	Healthy Volunteer
NCT02622477	Pre-clinical	Completed	Jun 1, 2014	Dec 1, 2016	Idiopathic Pulmonary Fibrosis
NCT02699879	Pre-clinical	Completed	Feb 16, 2012	Sep 15, 2016	Idiopathic Pulmonary Fibrosis
NCT00662038	Phase 3	Completed	Aug 1, 2008	Feb 1, 2016	Idiopathic Pulmonary Fibrosis

Competing Products

20 competing products in Covid19

See all competitors

Product	Company	Stage	Hype Score
AVIGAN + Placebo Comparator	Dr. Reddy's Laboratories	Phase 3	29
Favipiravir + Nitazoxanide	Strides Pharma	Phase 2	35
Icosapent ethyl	Amarin Corporation	Approved	25
GX-03 + Petrolatum ointment	Turn Therapeutics	Phase 2	25
Cytotoxic T Lymphocytes	Tevogen Bio	Phase 1	19
DS-5670a + Placebo	Daiichi Sankyo	Phase 1/2	32
Pegylated Interferon-α2b	Zydus Lifesciences	Phase 2	27
Baricitinib	Eli Lilly	Phase 3	32
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814	Eli Lilly	Phase 3	40
bamlanivimab	Eli Lilly	Approved	35
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222	AstraZeneca	Phase 1	25
Sacubitril / Valsartan Oral Tablet [Entresto] + Placebo	Novartis	Phase 1/2	32
Remdesivir + Remdesivir Placebo + Corticosteroid	Gilead Sciences	Phase 3	40
Remdesivir	Gilead Sciences	Pre-clinical	26
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + Corticosteroid	Gilead Sciences	Phase 3	40
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)	Pfizer	Phase 3	36
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine	Pfizer	Pre-clinical	26
Tofacitinib 10 mg + Placebo	Pfizer	Phase 3	40
BNT162b2	Pfizer	Phase 2	35
Anakinra + 0.9% Saline	Swedish Orphan Biovitrum	Phase 2	27